Reference

1. ^Li Q, Cheng T, Wang Y, Bryant SH (2010).„PubChem as a public resource for drug discovery.”.Drug Discov Today.15 (23-24): 1052—7.PMID 20970519.doi:10.1016/j.drudis.2010.10.003.  уреди
2. ^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry.4: 217—241.doi:10.1016/S1574-1400(08)00012-1. 
3. ^Hillman KL, Doze VA, Porter JE (2005).„Functional characterization of the beta-adrenergic receptor subtypes expressed by CA1 pyramidal cells in the rat hippocampus”.The Journal of Pharmacology and Experimental Therapeutics.314 (2): 561—7.PMID 15908513.doi:10.1124/jpet.105.084947. 
4. ^Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, Trevethick M (2008). „A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors”.Journal of Pharmacological and Toxicological Methods.58 (3): 189—97.PMID 18652905.doi:10.1016/j.vascn.2008.06.003. 
5. ^Mauriège P, De Pergola G, Berlan M, Lafontan M (1988).„Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta-1 antagonists”.Journal of Lipid Research.29 (5): 587—601.PMID 2900871.doi:10.1016/S0022-2275(20)38502-3. 
6. ^Emorine, L. J.; Marullo, S.; Briend-Sutren MM; et al. (1989).„Molecular characterization of the human beta 3-adrenergic receptor”.Science.245 (4922): 1118—21.PMID 2570461.doi:10.1126/science.2570461. CS1 одржавање: Експлицитна употреба et al. (веза)

Spoljašnje veze